NCT00628108 - Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 6 Months to 11 Months | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2008

Primary Completion Date

September 30, 2008

Study Completion Date

September 30, 2008

Conditions

Allergic RhinitisChronic Urticaria

Interventions

DRUG

Levocetirizine 1.25 mg

Levocetirizine dihydrochloride 1.25 mg (5 drops containing 5 mg/mL) dosed once a day for 2 weeks

OTHER

Placebo

Placebo oral liquid once a day for two weeks

Trial Locations (26)

Birmingham

Hot Springs

Jonesboro

Little Rock

Bakersfield

Crescent City

Huntington Beach

Los Angeles

Orange

Roseville

Stockton

Albany

Gainesville

Normal

Bridgeton

Omaha

Oklahoma City

Barnwell

Spartanburg

Kingsport

Austin

Dallas

El Paso

San Antonio

Sugarland

Richmond